Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
29
03
2023
accepted:
06
06
2023
revised:
11
07
2023
medline:
13
7
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Between January and March 2022, WHO conducted a global online survey to collect data on diagnostic capacities and treatment practices in different settings for four implantation mycoses: eumycetoma, actinomycetoma, cutaneous sporotrichosis and chromoblastomycosis. The survey investigated the type of diagnostic methods available in countries at various health system levels (tertiary, secondary, primary level) and the medicines used to treat implantation mycoses, with a view to understanding the level of drug repurposing for treatment of these diseases. 142 respondents from 47 countries, including all continents, contributed data: 60% were from middle-income countries, with 59% working at the tertiary level of the health system and 30% at the secondary level. The results presented in this article provide information on the current diagnostic capacity and treatment trends for both pharmacological and non-pharmacological interventions. In addition, the survey provides insight on refractory case rates, as well as other challenges, such as availability and affordability of medicines, especially in middle-income countries. Although the study has limitations, the survey-collected data confirms that drug repurposing is occurring for all four surveyed implantation mycoses. The implementation of an openly accessible global and/or a national treatment registry for implantation mycoses could contribute to address the gaps in epidemiological information and collect valuable observational data to inform treatment guidelines and clinical research.
Identifiants
pubmed: 37379338
doi: 10.1371/journal.pntd.0011443
pii: PNTD-D-23-00396
pmc: PMC10335693
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011443Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : FDA HHS
ID : U01 FD006603
Pays : United States
Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2022 Feb 4;16(2):e0010159
pubmed: 35120131
J Fungi (Basel). 2022 Sep 25;8(10):
pubmed: 36294569
Expert Opin Drug Discov. 2022 Jun;17(6):641-659
pubmed: 35612364
PLoS One. 2020 May 13;15(5):e0229630
pubmed: 32401759
Trop Med Infect Dis. 2019 Sep 24;4(4):
pubmed: 31554262
Br J Dermatol. 2023 Feb 10;188(2):157-159
pubmed: 36630642
PLoS Negl Trop Dis. 2020 Feb 25;14(2):e0008123
pubmed: 32097417
Lancet Infect Dis. 2021 Dec;21(12):e364-e374
pubmed: 34364529
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941
pubmed: 31904836